48 related articles for article (PubMed ID: 20827322)
1. Characterization of carotenoids in
Yu Z; Xia M; Li X; Wang R; Liu W; Zheng R; Wang Z; Yang L; Shi Y
Front Chem; 2022; 10():1052000. PubMed ID: 36426103
[TBL] [Abstract][Full Text] [Related]
2. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.
Parolia A; Venalainen E; Xue H; Mather R; Lin D; Wu R; Pucci P; Rogalski J; Evans JR; Feng F; Collins CC; Wang Y; Crea F
Mol Oncol; 2019 May; 13(5):1121-1136. PubMed ID: 30776192
[TBL] [Abstract][Full Text] [Related]
3. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial.
Borst SE; Yarrow JF; Conover CF; Nseyo U; Meuleman JR; Lipinska JA; Braith RW; Beck DT; Martin JS; Morrow M; Roessner S; Beggs LA; McCoy SC; Cannady DF; Shuster JJ
Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E433-42. PubMed ID: 24326421
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride for the treatment of prostate-related conditions.
Slater S; Dumas C; Bubley G
Expert Opin Drug Saf; 2012 Mar; 11(2):325-30. PubMed ID: 22316171
[TBL] [Abstract][Full Text] [Related]
6. Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.
Alisky JM; Tang Y; Habermehl GK; Iczkowski KA
Int J Clin Exp Med; 2010 Jul; 3(3):245-7. PubMed ID: 20827322
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
8. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
9. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
Marberger M; Roehrborn CG; Marks LS; Wilson T; Rittmaster RS
J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
[TBL] [Abstract][Full Text] [Related]
10. Effects of Curcumin Combined With the 5-alpha Reductase Inhibitor Dutasteride on LNCaP Prostate Cancer Cells.
Nakayama A; Ide H; Lu Y; Takei A; Fukuda K; Osaka A; Arai G; Horie S; Okada H; Saito K
In Vivo; 2021; 35(3):1443-1450. PubMed ID: 33910821
[TBL] [Abstract][Full Text] [Related]
11. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
12. The benefits and risks of testosterone replacement therapy: a review.
Bassil N; Alkaade S; Morley JE
Ther Clin Risk Manag; 2009 Jun; 5(3):427-48. PubMed ID: 19707253
[TBL] [Abstract][Full Text] [Related]
13. Rapidly shifting concepts regarding androgens and prostate cancer.
Morgentaler A
ScientificWorldJournal; 2009 Jul; 9():685-90. PubMed ID: 19649507
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiles of finasteride effects on prostate carcinogenesis.
Li J; Kim J
Cancer Prev Res (Phila); 2009 Jun; 2(6):518-24. PubMed ID: 19491289
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer?
Delongchamps NB; de la Roza G; Chandan V; Jones R; Sunheimer R; Threatte G; Jumbelic M; Haas GP
J Urol; 2008 May; 179(5):1736-40. PubMed ID: 18343414
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
